Persistent Systems Unleashes AI Innovations for Drug Discovery with NVIDIA Collaboration

Persistent Systems, a leader in Digital Engineering and Enterprise Modernization, has recently partnered with NVIDIA to transform drug discovery in the Healthcare and Life Sciences (HLS) sector by leveraging AI technology. This collaboration aims to alleviate the challenges faced by HLS organizations, which often operate in complex and regulated environments, by enabling faster, more efficient drug development processes.

The stakes are high for HLS companies as they strive to innovate amidst growing regulatory scrutiny and the demand for more effective therapies. In response, Persistent Systems is combining its considerable industry expertise with NVIDIA's powerful full-stack AI platform. This partnership is particularly focused on computational drug discovery, where cutting-edge AI techniques will enhance research outcomes.

The core of this collaboration rests on the development of the Generative Molecules and Virtual Screening (GenMoIVS) solution, built using NVIDIA’s advanced platforms. The goal is to enable high-fidelity molecular simulations and virtual screening, allowing researchers to model the behavior of biological and chemical compounds more realistically before conducting experiments in the laboratory. This approach not only saves time but also mitigates risks associated with early-stage drug discovery.

Through GenMoIVS, Persistent Systems aims to provide biopharmaceutical companies with a transformative tool for drug development. The solution will act as an intelligent agent to facilitate various stages of drug discovery—such as virtual screening, candidate prioritization, and experimental planning—by translating digital simulations into actionable data for laboratory experiments. This simulation-led methodology allows organizations to make more informed decisions rapidly, driving speed and efficacy in clinical development pipelines.

In practical terms, using NVIDIA AI Enterprise, Persistent will enable specialized research and development cases, particularly in preclinical research settings. As a result, the pharmaceutical sector can transition from extensive and time-consuming experimental processes to generative, AI-driven methodologies within days. With this level of efficiency, researchers can refine their focus on the most promising candidates faster than ever before.

Furthermore, Persistent Systems plans to enhance its GenMoIVS solution by integrating NVIDIA’s Nemotron open models. This integration will empower Persistent to deliver very high-quality AI outputs that cater to the specific needs of life sciences R&D. Through systematic use of NVIDIA accelerated computing technologies, Persistent can deploy production-grade AI applications to optimize real-time decision-making within research environments that are typically heavy with regulations and compliance requirements.

Their executive team is optimistic about the union of AI technology with traditional drug discovery methods. Ganesh Nathella, Executive Vice President and General Manager of HLS Business at Persistent, emphasized that the collaboration reflects the industry’s need for speed and efficiency without compromising scientific integrity. By harnessing generative AI tools, they aim to empower companies to make informed choices and bring new therapies to market expediently.

NVIDIA's Vice President of Enterprise Software, John Fanelli, echoed this urgency, noting that the global demand for innovative therapies continues to rise. The integration of AI into drug discovery is not just an enhancement but a necessary evolution for the life sciences industry. The partnership between NVIDIA and Persistent Systems exemplifies how technology can accelerate the pace of research and provide businesses with essential tools for future success.

Persistent Systems is more than just a service provider; it is a global entity committed to driving innovation across various fields. With over 26,500 employees and a presence in 18 countries, the company is well-positioned to lead the digital transformation of industries through AI and cloud solutions. Above all, it remains focused on sustainability and responsible business practices, confirming its stature as a forward-thinking leader in technology.

In conclusion, this partnership between Persistent Systems and NVIDIA marks a revolutionary shift in drug discovery. By combining their strengths, these two industry giants are well-poised to create a new standard for research and development in healthcare, one that is faster, more efficient, and capable of meeting the world's urgent need for new medical therapies.